October 25, 2014
Amgen will pay $762 million to settle litigation that accuses the drugmaker of marketing the anemia drug Aranesp for unapproved uses.
A law firm involved in the case says the Thousand Oaks, Calif., company will pay a $612 million civil settlement, $136 million in criminal fines and a $14 million forfeiture.
Amgen Inc. says it entered a conditional guilty plea to a misdemeanor count of misbranding Aranesp. The company took a $780 million charge last year for a possible settlement.
Amgen develops biologic medicines, or drugs produced by living cells rather than by mixing chemicals. Its settlement marks the latest between the U.S. Department of Justice and a drugmaker over improper marketing allegations.
Doctors can prescribe drugs for unapproved uses, but companies aren't allowed to market drugs for those uses.
Copyright 2014 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.